

ATP-PRO®

America is Looking for an Answer

- Cardiovascular disease is the leading cause of death in America...
- Fibromyalgia is reaching epidemic proportions...
- High performance sports are a multi-billion industry...
- Energy needs are a top reason people purchase nutritional supplements...
- Athletes are looking for ways to safely increase muscle gains and speed recovery...

There is an Answer

A Product With:

- 20 patents
- 100+ peer-reviewed and published scientific and clinical studies
- Numerous features in major medical journals
- Pharmaceutical grade certified materials
- Proven and documented results
- Applications for individuals in all walks of life and health challenges

Eniva ATP-Pro® is the answer. It provides your body with a patented form of D-Ribose, the most fundamental source of energy your body can have. D-Ribose is what your body uses to naturally build its energy stores. Taking Eniva ATP-Pro helps your body quickly replace energy levels that have been depleted by hard work, exercise, or health challenges.

It is well known that strenuous work, high-intensity exercise, and many health challenge conditions contribute to a depletion of the energy pool leading to fatigue, muscle soreness and stiffness that negatively impact exercise tolerance and quality of life. And this concern is universal, all the way from top conditioned athletes, to weekend warriors, to patients recovering from serious illness. Science has also shown that once reduced, it takes several days for energy levels to return to normal, and in the case of ischemia (low oxygen), they may never recover without the supplemental help of the D-Ribose in ATP-Pro.

Energy and cardiovascular health are top reasons consumers buy nutritional supplements or functional foods and beverages. ATP-Pro stands alone in its ability to deliver a natural, demonstrable, safe and patent-protected benefit to health conscious consumers.



*Replenishing the Essence
of Vibrant Health™*

PATENTS AND CLINICAL STUDIES SHOWING

- Treatment of heart disease and congestive heart failure*
- Treatment of fibromyalgia*
- Dramatic increases in muscle growth*
- Treatment of low oxygen conditions and associated complications*
- Rapid athletic recovery*
- Increased energy levels and anaerobic thresholds*

***This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease; research is ongoing.**

INTELLECTUAL PROPERTY:

The D-Ribose used in the Eniva ATP-Pro product has been granted patent protection covering a broad range of nutritional and pharmaceutical uses for D-Ribose. These include such things as a) use of D-Ribose in cardiac diagnosis, b) energy enhancement, c) use for the prevention of muscle soreness, stiffness and cramping, d) use to treat ischemic tissue, and e) use to treat fibromyalgia.

SOME OF THE PATENTS:

- U.S. patent number 6,159,942 covers the oral use of D-Ribose as an energy enhancing supplement when taken alone or in combination with other ingredients in drinks, energy bars, dietary supplements or other food and nutrition products.
- U.S. patent number 6,159,943 covers the use of D-Ribose for the prevention of muscle soreness and cramping following muscle over work or in cases of restricted circulation.
- U.S. patents 4,719,201 and 4,605,644 cover the use of D-Ribose alone or in combination with adenine for treating ischemic tissue.
- U.S. patents and cover the use of D-Ribose to unmask hibernating myocardium and aid in perfusion imaging diagnosis, respectively.
- Three patent applications, including use of D-Ribose in treatment of fibromyalgia, have been allowed in the United Kingdom and several are filed internationally under the Patent Cooperation Treaty designating all treaty countries.
- Several additional patents are pending.

SCIENTIFIC REFERENCES

1. Andreoli S. Mechanisms of Endothelial Cell ATP Depletion after Oxidant Injury. *Pediatric Res.* 1989; 25(1): 97-100
2. Angello D, Wilson R, Gee D, Perlmutter N. Recovery of Myocardial Function and Thallium 201 Redistribution Using Ribose. *Am J Card Imag.* 1989; 3(4): 256-265.
3. Asimakis G, Zwischenberger J, Inners-McBride K, Sordahl L, Conti V. Posts ischemic Recovery of Mitochondrial Adenine Nucleotides in the Heart. *Circ.* 1992; 85(6): 2212-2220.
4. Baldwin D, McFalls E, Jaimes D, Fashingbauer P, Nemzek T, Ward H. Myocardial Glucose Metabolism and ATP Levels are Decreased Two Days after Global Ischemia. *J Surg Res.* 1996; 63: 35-38.
5. Chatham J, Challiss R, Radda G, Seymour A. Studies of the Protective Effect of Ribose in Myocardial Ischaemia by using ³¹P-Nuclear Magnetic Resonance Spectroscopy. *Biochem Soc Proc.* 1985; 13: 885-88.
6. Clay MA, Stewart-Richardson P, Tasset D, Williams J. Chronic Alcoholic Cardiomyopathy: Protection of the Isolated Ischemic Working Heart by Ribose. *Biochem Internat.* 1988; 17(5): 791-800.
7. Cohen M, Charney R, Hershman R, Fuster V, Gorlin R, Francis X. Reversal of Chronic Ischemic Myocardial Dysfunction After Transluminal Coronary Angioplasty. *JACC.* 1988; 12(5): 1193-1198.
8. Dow J, Nigdikar S, Bowditch J. Adenine Nucleotide Synthesis de novo in Mature Rat Cardiac Myocytes. *Biochim Biophys Acta.* 1985; 847(2): 223-227.
9. Einzig S, St. Cyr J, Bianco R, Schneider J, Lorenz E, Foker J. Myocardial ATP Repletion with Ribose Infusion. *Pediatr Res.* 1985; 19: 127A.
10. Einzig S, St. Cyr J, Schneider J, Bianco R, Foker J. Maintained Myocardial ATP with Long Term Ribose. *Pediatr Res.* 1986; 20(4 pt 2): 169A.
11. Gao W, Liu Y, Marban E. Selective Effects of Oxygen Free Radicals on Excitation-Contraction Coupling in Ventricular Muscle. *Circ.* 1996; 94: 2597-2604.
12. Geisbuhler T, Schwager T. Ribose-Enhanced Synthesis of UTP, CTP, and GTP From Parent Nucleosides in Cardiac Myocytes. *J Mol Cell Cardiol.* 1998; 30(4): 879-887.
13. Goncalves RP, GC Bennett, CP Leblond. Fate of 3H-ribose in the rat as detected by autoradiography. *Anat Rec* 165:543-557, 1969.
14. Gradus-Pizlo I, SG Sawada, S Lewis, S Khouri, DS Segar, R Kovacs, H Feigenbaum. Effect of D-ribose on the detection of the hibernating myocardium during the low dose dobutamine stress echocardiography. *Circ* 100(18):3394, 1999.
15. Gross M, S Reiter, N Zollner. Metabolism of D-ribose administered to healthy persons and to patients with myoadenylate deaminase deficiency. *Klin Wochenschr* 67:1205-1213, 1989.
16. Gross G, Auchampac J, Role of ATP Dependent Potassium Channels in Myocardial Ischaemia. *Cardiovasc Res.* 1992; 26: 1011-1016.

17. Haas G, DeBoer L, O'Keefe E, Bodenhamer R, Geffin G, Drop L, Teplick R, Daggett W. Reduction of postischemic myocardial dysfunction by substrate repletion during reperfusion. *Circ.* 1984; 70: 165-174.
18. Hegewald MG, RT Palac, D Angello, NS Perlmutter, RA Wilson. Ribose infusion accelerates thallium redistribution with early imaging compared with late 24-hour imaging without ribose. *JACC* 18:1671-1681, 1991.
19. Ibel H, Zimmer HG. Metabolic Recovery Following Temporary Regional Myocardial Ischemia in the Rat. *J Mo. Cell Cardiol.* 1986; 18(Suppl 4), 61-65.
20. Illien S, Omran H, MacCarter D, St. Cyr J. Ribose Improves Myocardial Function in Congestive Heart Failure. *FASEB J.* 2001; 15(5): A1142.
21. Kalsi K, Smolenski R, Yacoub M. Effects of Nucleoside Transport Inhibitors and Adenine/Ribose Supply on ATP Concentration and Adenosine Production in Cardiac Myocytes. *Moll. Cell. BiolChem.* 1998; 180(1-2): 193-199.
22. Keith M. Increased Oxidative Stress in Patients with Congestive Heart Failure. *J Am Coll Cardiol.* 1998; 31(6): 1352-1356.
23. Koumi S, Martin R, Sato R. Alterations in ATP-Sensitive Potassium Channel Sensitivity to ATP in Failing Human Hearts. *Am J Physiol.* 1997; 272(41): H1656-H1665.
24. Lanoue K, Watts J, Koch C. Adenine Nucleotide Transport During Cardiac Ischemia. *Am J Physiol.* 1981; 24: H663-H671.
25. Lewandowski E, Yu X, LaNoue K, White L, Doumen C, O'Donnell M. Altered Metabolic Exchange Between Subcellular Compartments in Intact Posts ischemic Rabbit Hearts. *Circ Res.* 1997; 81: 165-175.
26. Lortet S, H-G Zimmer. Functional and metabolic effects of ribose in combination with prazosin, verapamil and metoprolol in rats in vivo. *Cardiovasc Res* 23:702-708, 1989.
27. Mahoney J, Sako E, Seymour K, Marquardt C, Foker J. A Comparison of different Carbohydrates as Substrates for the Isolated Working Heart. *J Surg Res.* 1989; 47: 530-534.
28. Mahoney J. Recovery of Posts ischemic Myocardial ATP Levels and Hexosemonophosphate Shunt Activity. *Med Hypoth.* 1990; 31: 21-23.
29. Mauser M, Hoffmeister H, Nienaber C, Schaper W. Influence of Ribose, Adenosine and "AICAR" on the Rate of Myocardial Adenosine Triphosphate Synthesis during Reperfusion after Coronary Artery Occlusion in the Dog. *Circ Res.* 1985; 56: 220-230.
30. Muller C, Zimmer H, Gross M, Gresser U, Brotsack I, Wehling M, Pliml W. Effect of Ribose on Cardiac Adenine Nucleotides in a Donor Model for Heart Transplantation. *Eur J Med Res.* Dec 1989; 554-558.
31. Omran H, Illien S, MacCarter D, St. Cyr J. Ribose Improves Myocardial Function and Quality of Life in Congestive Heart Failure Patients. *J Mol Cell Cardiol.* 2001; 33(6): A173.

Additional References on file at Eniva Corporation.

www.eniva.com

© Eniva Corporation
Minneapolis, MN, 2007
All Rights Reserved
0346.03/07



Printed on recycled paper
Please recycle.

ATP-PRO

Eniva's Patented Energy Enhancer

32. Pasque M, Spray T, Peliom G, van Trig P, Peyton R, Currie W, Wechsler A. Ribose-Enhanced Myocardial Recovery following Ischemia in the Isolated Working Rat Heart. *J Thorac Cardiovasc Surg.* 1982; 83(3): 390-398.
33. Pasque M, Wechsler A. Metabolic Intervention to Affect Myocardial Recovery Following Ischemia. *Ann Surg.* 1984; 200: 1-10.
34. Pauly D, Pepine C. D-Ribose as a Supplement for Cardiac Energy Metabolism. *J Cardiovasc Pharmacol Ther.* 2000; 5(4): 249-258.
35. Perlmutter NS, RA Wilson, DA Angello, RT Palac, J Lin, BG Brown. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. *J Nucl Med* 32:193-200, 1991.
36. Pliml W, von Arnim T, Stablein A, Hofmann H, Zimmer H, Erdmann E. Effects of Ribose on Exercise-Induced Ischaemia in Stable Coronary Artery Disease. *Lancet.* Aug 1992; 340: 507-510.
37. Pouleur H. Diastolic Dysfunction and Myocardial Energetics. *Eur Heart J.* 1990; 11(Suppl C): 30-34.
38. Reibel D, Rovetto M. Myocardial ATP Synthesis and Mechanical Function Following Oxygen Deficiency. *Am J Physiol.* 1978; 234 (5): H620-H624.
39. Reimer K, Hill M, Jennings R. Prolonged Depletion of ATP and of the Adenine Nucleotide Pool due to Delayed Resynthesis of Adenine Nucleotides following Reversible Myocardial Ischemic Injury in Dogs. *J Mol Cell Cardiol.* 1981; 13: 229-239.
40. Sami H, Bittar N. The Effect of Ribose Administration on Contractile Recovery Following Brief Periods of Ischemia. *Anesthesiol.* 1987; 67(3A): A74.
41. Schneider J, St. Cyr J, Mahoney J, Bianco R, Ring W, Foker J. Recovery of ATP and Return of Function After Global Ischemia. *Circ.* 1985; 72(4 pt 2): III-298.
42. Segal S, J Foley. The metabolism of D-ribose in man. *J Clin Invest.* 719-735, 1958.
43. Seifert J, Subudhi A, Fu M-X, Riska K, John J. The Effects of Ribose Ingestion on Indices of Free Radical Production During Hypoxic Exercise. *Free Rad Biol Med.* 2002; 33(suppl 1): S269.
44. Siess M, Delabar U, Seifart H. Cardiac Synthesis and Degradation of Pyridine Nucleotides and the Level of Energy-Rich Phosphates Influenced by Various Precursors. *Adv Myocardiol.* 1983; 4: 287-308.
45. Smolenski R, Kalsi K, Zych M, Kochan Z, Yacoub M. Effects of Adenine/Ribose Supply on Adenosine Production and ATP Concentration in Adenosine Kinase-Inhibited Cardiac Cells. *Adv Exp Med Biol.* 1998; 431: 385-388.
46. Smolenski R, Kalsi K, Zych M, Kochan Z, Yacoub M. Adenine/Ribose Supply Increases Adenosine Production and Protects ATP Pool in Adenosine Kinase-Inhibited Cardiac Cells. *J Mol Cell Cardiol.* 1998; 30(3): 673-683.
47. St. Cyr J, Bianco R, Foker J. Myocardial High-Energy Phosphate Levels in Cardiomyopathic Turkeys. *J Surg Res.* 1986; 41: 256-259.
48. St. Cyr J, Ward H, Kriett J, Alyono D, Einzig S, Bianco R, Anderson R, Foker J. Long-Term Model for Evaluation of Myocardial Metabolic Recovery Following Global Ischemia. *Adv Exp Med Biol.* 1986; 194: 401-441.
49. St. Cyr J, Bianco R, Schneider J, Mahoney J, Tveter K, Einzig S, Foker J. Enhanced High Energy Phosphate Recovery with Ribose Infusion after Global Myocardial Ischemia in a Canine Model. *J Surg Res.* 1989; 46(2): 157-162.
50. Swain JL, Sabina R, McHale P, Greenfield J, Holmes E. Prolonged Myocardial Nucleotide Depletion after Brief Ischemia in the Open-Chest Dog. *Am J Physiol.* 1982; 242: H818-H826.

 ENIVA®